mRNA Vaccines for Melanoma

The fight against skin cancer has reached a turning point with recent data from Moderna and Merck. Their collaboration involves a personalized mRNA cancer vaccine used alongside the immunotherapy drug Keytruda. Clinical trials show this combination significantly reduces the risk of melanoma returning in high-risk patients. This article explains the science behind the treatment, the specific trial results, and what this means for the future of oncology.

The Moderna and Merck Breakthrough

For years, scientists have theorized that messenger RNA (mRNA) technology could train the immune system to target cancer cells. While the world became familiar with mRNA through COVID-19 vaccines, Moderna has been working on cancer applications for much longer.

The specific treatment in question is mRNA-4157 (V940). It is an investigational personalized mRNA cancer vaccine developed by Moderna. When combined with Keytruda (pembrolizumab), a standard-of-care immunotherapy drug developed by Merck, the results have outperformed the use of Keytruda alone.

Key Findings from the Phase 2b Trial

The excitement stems from the KEYNOTE-942 Phase 2b clinical trial. This study focused on patients with Stage III or IV melanoma who had already undergone surgery to remove their tumors. These patients are generally considered at high risk for the cancer coming back.

The trial produced concrete, promising numbers:

  • Recurrence Reduction: Patients receiving the combination therapy showed a 49% reduction in the risk of recurrence or death compared to those who only received Keytruda. This data comes from a three-year follow-up analysis presented in late 2023.
  • Distant Metastasis: The combination also reduced the risk of the cancer spreading to other parts of the body (distant metastasis) by 62% compared to Keytruda alone.

These statistics suggest that adding the personalized vaccine does more than just boost the immune system generally; it gives the body a specific “wanted poster” for the cancer cells.

How the Personalized Vaccine Works

Unlike a flu shot which is the same for everyone, mRNA-4157 is a personalized neoantigen therapy. This means every single dose is custom-made for the individual patient. The process involves sophisticated science and logistics.

1. Sequencing the Tumor

The process begins after a patient has their tumor surgically removed. Doctors take a sample of the tumor tissue and a sample of the patient’s healthy blood. These samples are sent to a lab for DNA sequencing.

2. Identifying Mutations

Computers compare the DNA of the tumor against the healthy blood to identify mutations unique to that specific cancer. These mutations are called neoantigens.

3. Manufacturing the Vaccine

Moderna uses an algorithm to select up to 34 specific neoantigens that are most likely to trigger a strong immune response. They then manufacture a synthetic strand of mRNA that codes for these 34 targets. This process takes about six to eight weeks.

4. Training the Immune System

Once injected, the mRNA instructs the patient’s cells to produce these harmless protein fragments (the neoantigens). The immune system recognizes these fragments as foreign invaders.

Because Keytruda is a checkpoint inhibitor, it works by removing the “brakes” from the immune system (specifically blocking the PD-1 pathway). The vaccine, simultaneously, pushes the “gas” by directing T-cells to hunt down cells displaying the specific mutations identified in step two. This two-pronged attack prevents the cancer cells from hiding or surviving.

Safety and Side Effects

Any new treatment raises questions about safety. The Phase 2b trial monitored patients closely for adverse effects. The safety profile of the combination therapy was generally consistent with what doctors see with standard immunotherapy.

The most common side effects reported specifically related to the mRNA vaccine included:

  • Fatigue
  • Pain at the injection site
  • Chills and fever (flu-like symptoms)

These symptoms indicate that the immune system is responding to the vaccine. Importantly, the addition of the mRNA vaccine did not significantly increase the rate of severe (Grade 3-4) adverse events compared to Keytruda alone.

Regulatory Status and Future Trials

Based on the strength of the Phase 2b data, the U.S. Food and Drug Administration (FDA) granted the treatment Breakthrough Therapy Designation in February 2023. This designation is intended to expedite the development and review of drugs that treat serious conditions.

However, the treatment is not yet available at your local oncologist’s office. To gain full approval, the companies must prove the results in a larger group of people.

The Phase 3 Trial (Interpath-001)

Moderna and Merck have launched a pivotal Phase 3 trial named Interpath-001.

  • Scope: This trial aims to recruit approximately 1,089 patients globally.
  • Objective: It will further evaluate the safety and efficacy of mRNA-4157 combined with Keytruda versus Keytruda alone.
  • Significance: If this trial replicates the success of the Phase 2b study, it will likely lead to FDA approval and commercial availability.

Expanding Beyond Melanoma

The success in melanoma has prompted the companies to test this technology in other tumor types. A Phase 3 trial (Interpath-002) has already been initiated to test the same vaccine-immunotherapy combination in patients with non-small cell lung cancer (NSCLC). This suggests the platform could theoretically be adapted for many solid tumor cancers that have high mutation rates.

Frequently Asked Questions

Is the mRNA melanoma vaccine available to the public? No, not yet. The treatment is currently investigational. It is only available to patients who qualify for participation in specific clinical trials, such as the Phase 3 Interpath-001 study.

Is this vaccine a cure for melanoma? The vaccine is designed as an “adjuvant” therapy. This means it is used after surgery to prevent the cancer from coming back. While the data shows it significantly reduces the risk of recurrence, calling it a guaranteed “cure” is premature. It is a preventative measure for high-risk patients.

How does this differ from the COVID-19 mRNA vaccine? Both use mRNA to deliver instructions to cells. However, the COVID-19 vaccine is “prophylactic” (preventative against a virus you don’t have yet) and is identical for everyone. The melanoma vaccine is “therapeutic” (treating a disease you already have/had) and is fully personalized. It requires your specific tumor DNA to be manufactured.

How long does it take to make the vaccine? Currently, the turnaround time from obtaining the tumor sample to treating the patient is approximately six to eight weeks. As manufacturing capabilities scale up, the companies aim to reduce this timeline.